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1. Introduction 
Renal cell carcinoma (RCC) ist the 3rd most common urologic cancer leading to an 
estimated 271 000 new cancer cases worldwide each year (Ferlay et al. 2010). RCC is 
generally associated with poor prognosis because of late diagnosis and bad responsiveness 
to classical radio- and chemotherapy. For a long period of time immunotherapy with IL-2 or 
Interferon alpha (IFN) have been the only therapeutic options to treat advanced stage 
RCCs. In recent years targeted therapy with tyrosine kinase inhibitors (TKIs; Sunitinib, 
Sorafenib) or mTor inhibitors (Everolimus, Temsirolimus) has replaced cytokine based 
immunotherapy as a first line treatment in the management of metastatic RCCs (mRCC). 
IFN is nevertheless still playing an important role in the treatment of mRCC not as a 
monotherapy, but rather in combination with the antibody Bevacizumab which is directed 
against proangiogenic vascular endothelial growth factor (VEGF).  
Despite these recent improvements resistance to this new class of drugs frequently occurs 
and curative treatment of RCC is still only possible by surgical resection of the tumor mass 
at an early non-metastatic stage (Rini & Atkins 2009). A lot of effort has therefore been put 
into the development of a targeted immunotherapeutic approach that aims at the in vivo 
induction or reinforcement of an anti tumor immune response. 
2. Cancer immunotherapy in the course of history  
The underlying idea that the immune system is able to recognise and kill transformed cells 
is actually not new (Parish 2003). As early as the 19th century William Coley and others 
noticed that cancer patients suffering from a bacterial infection sometimes experienced 
tumor regression. William Coley was also the first to translate this observation into clinical 
practice by treating cancer patients with a bacterial preparation of Streptococcus pyogenes 
known as Coley’s toxin (Coley 1893). In 1909 Paul Ehrlich evaluated the role of the immune 
system in tumor control and suggested that without the immune system cancers would 
occur in much higher frequency (Ehrlich 1909). Unfortunately it took more than half a 
century before Ehrlich’s idea regained attention. First experimental evidence during the 
1950s could show that syngenic animals could be immunized against transplantable tumors. 
In the early 1960s Lewis Thomas argued that long-lived organisms must have developed 
mechanisms that resemble homograft rejection in order to counter neoplastic diseases 
www.intechopen.com
 Emerging Research and Treatments in Renal Cell Carcinoma 
 
194 
(Lawrence 1959). Based on Thomas’ views Frank M. Burnet formulated in 1967 his 
revolutionary „Immunosurveillance Theory“ in which he stated that immune cells were 
constantly surveying host tissues for the presence of transformed cells that could be 
recognized by neo-antigens acquired during the transformation process (Burnet 1967). 
However Burnet’s idea remained controversial simply because many people could not 
believe that the immune system could properly differentiate between healthy tissue and 
transformed cancer cells. Experiments with athymic nude mice also argued against Burnets 
idea (Stutman 1979). Despite their supposed lack of mature T cells (which was later shown 
to be not completely true (Maleckar & Sherman 1987)) these mice had no higher incidence in 
tumor development as originally predicted by Ehrlich. Since the late 80s, more and more 
evidence accumulated that revived the immunosurveillance theory. The discovery of tumor 
associated antigens (TAA) in mice and humans as well as the observation that truly 
immunodeficient knockout mice (e.g. RAG2-/-, STAT1-/-) really showed a higher incidence in 
cancer development finally proved Burnets idea. 
3. Immunotherapeutical studies in RCC  
RCC, along with melanoma, are considered to be the most immunogenic tumor in humans. 
This is based on the occurence of spontaneous regressions even in metastatic disease (Lokich 
1997), the high amount of lymphocytic infiltrates found in tumor tissue (Van den Hove et al. 
1997) and the comparably good response to nonspecific immunotherapy with cytokines like 
IL-2 or IFN, at least in some part of the patients (10-20%) (Negrier et al. 1998). First clinical 
trials using a specific immunotherapy for RCC were therefore conducted during the mid -
90s already. Table 1 provides a comprehensive summary of published results regarding 
anti-tumor vaccination approaches from that time until today. Many different strategies 
involving lysate from autologous tumor tissue, allogenic tumor cell lines, whole tumor cell 
RNA as well as defined antigens (e.g. peptides derived from TAAs CAIX or MUC1) have 
been used. In most cases these antigens were applied in combination with an adjuvant (e.g. 
GM-CSF, BCG or incomplete Freunds adjuvant) or after loading onto dendritic cells (DCs) 
usually from the same patient. Dendritic cells are professional antigen presenting cells that 
have the capacity to take up tumor derived products spontaneously (in some trials also 
inforced by electrofusion with tumor cells) and to present antigen derived peptides via HLA 
class I and II molecules to cytotoxic- and also T helper cells. In most trials dendritic cells 
were generated from autologous peripheral blood derived monocytes or CD34+ bone 
marrow cells that can both develop ex vivo into immature dendritic cells (iDCs). More recent 
studies almost uniformly apply a cytokine maturation step to generate mature dendritic 
cells (mDCs) as iDCs have been shown to posess tolerogenic rather than immune 
stimulatory functionality (Figdor et al. 2004). Keyhole limpet hemocyanin has been also 
applied in many trials as an immunostimulant because it was previously shown to improve 
dendritic cell based vaccinations by inducing a potent CD4+ T helper cell response at least in 
mouse models (Shimizu et al. 2001). Other approaches to enhance the immunogenicity of the 
vaccine have been tried by virally transducing autologous tumor cells and allogenic cell 
lines with cytokines (GM-CSF, IL2) or T-cell costimulatory molecule CD80 (B7.1).  
Vaccination with all these different approaches has proven to be well tolerated and side effects 
have been rare and were usually limited to allergic reactions at the site of injection as well as 
induration or erythema. In trials in which additional cytokine treatment (IL-2, IFN) was 
employed, further side effects like fatigue, fever, vomiting and hypotension could be observed. 
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In some cases systemic application of high dose cytokines can however also lead to serious 
and life-threatening side effects.  These symptoms have been known for a long time to also 








*Number of patients treated versus number of patients in control group in brackets. mRCC: metastatic 
renal cell carcinoma, ccRCC: clear cell renal cell carcinoma, autol.: autologous, allog.: allogenic, mDC: 
mature dendritic cells, iDC: immature dendritic cells, BCG: Bacille Calmette Guerin, IFA: Incomplete 
Freunds adjuvant CP: Cyclophosphamide, CR: complete response, PR: partial response, MR: mixed 
response, OR: objective response, SD: stable disease, PD: progressive disease, OS.: overall survival RFS.: 
regression free survival, PFS: progression free survival, DFS: disease free survival.  
Table 1. Immunotherapeutical studies in RCC 
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Apart from the tumor vaccination studies mentioned above other approaches involving the 
transfer of leukocytes such as adoptive T-cell transfer and even stem cell transplantation 
have been applied in some cases. Allogenic stem cell transplantation has been used 
succesfully for several decades in hematological cancers. Lymphocytes, in particular T-cells 
of HLA identical donors, are thought to exert a graft-vs-leukaemia effect mainly by 
recognition of minor histocompatibility antigens on recipient tissues (Bleakley & Riddell 
2004) but probably also tumor cell specific antigens (Tykodi et al. 2004). The curative or 
graft-vs-leukaemia effect (GvL) therefore often directly correlates with the appearance of 
graft vs host disease (GvHD). The use of stem cell transplantation in solid tumors has been 
shown to provide a similiar graft-vs-tumor (GvT) effect in renal cell carcinoma, but also in 
ovarian (Bay et al. 2002) and breast cancer patients (Bishop et al. 2004). In the context of solid 
tumors non-myeloablative regimens have been preferred to avoid the substantial side effects 
of myeloablation with high dose chemotherapy and irradiation. Engraftment thus does not 
lead to complete substitution of the host’s immune system but rather to a chimeric state 
incorperationg both the recipient’s and the donor’s hematological system. First studies of 
non-myeloablative allogenic stem cell transplantation (NST) in 17 mRCC patients showed 
quite promising results (Childs et al. 2000) with partial regression in over 50% including 
three patients with prolonged complete response. Further studies have been conducted (for 
a comprehensive overview see (Demirer et al. 2008)) with small patient numbers and 
varying response rates ranging from 0% (Rini et al. 2006) to more than 50% (Bregni et al. 
2002) . However, NST is also facing several other difficulties. Besides the need for an HLA 
matched donor, severe and sometimes fatal complications from transplantation and 
subsequent GvHD can occur. Furthermore the time from treatment to response can take 
several months and in order to avoid graft rejection, patients have to be kept in an 
immunosuppressive state which allows for and might even accelerate rapid disease 
progression.  
Adoptive T cell transfer in RCC has played a rather minor role compared to trials in other 
immunogenic tumors, especially in melanoma. Initial studies with isolated and ex vivo 
expanded tumor infiltrating lymphocytes (TILs) that have been reinfused into the patient 
usually in combination with IL-2, showed only modest response (Topalian et al. 1988; 
Kradin et al. 1989). In a larger phase III trial involving 160 patients with metastatic RCC, 
treatment with ex vivo expanded TILs and IL-2  showed no benefit compared to IL-2 alone 
(Figlin et al. 1999). Because of these disappointing results and because of the lack of tumor 
specific T-cell epitopes further use of (antigen specific) adoptive T-cell transfer has been 
limited although recently the usage of gammadelta T cells in RCC patients has moved into 
the focus of ongoing research (Bennouna et al. 2008; Kobayashi et al. 2010). In order to 
complete the picture of current immunotherapeutic approaches, WX-G250 (Girentuximab) 
has to be mentioned. This is an antibody developed by Wilex that is specifically intended for 
adjuvant use in non-metastatic RCC patients and is currently undergoing Phase III clinical 
trials (Reichert 2011). The chimeric IgG1 antibody is directed against Carbonic anhydrase 9, 
which is a tumor associated antigen expressed by more than 90% of clear cell renal cell 
carcinoma. Data from a recent Phase I/II trial of Girentuximab in combination with IFN for 
metastatic RCC patients have shown good tolerability, safety and also clinical benefit 
(Siebels et al. 2011).  
Considering the diversity of different immunotherapeutic approaches, especially in tumor 
vaccination, the question remains why many of these studies failed or showed rather limited 
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clinical success, with only a few trials progressing to clinical phase III. In order to answer 
this question we will first look at the main problem of all immunotherapeutic approaches, 
namely the ability of a tumor to escape a directed immune response by inducing an 
immunosuppresive environment. In this context we will also discuss methodological 
deficiencies and contradictions that have contributed to clinical failure and describe more 
promising directions for future immunotherapy. 
4. Immunosuppression and tumor escape 
As mentioned above, renal cell carcinomas, like other tumors, are highly infiltrated by 
leukocytes and especially T cells (> 60%) mainly of the CD8+ rather than the CD4+ 
phenotype. Natural killer cells have also been found to be enriched within the TIL 
population in some studies at least whereas B cells make up only a minor subset. (Van den 
Hove, Van Gool et al. 1997). Infiltrating T cells are predominantly of the antigen experienced 
effector memory type (TEM), and CD8+ cells also encompass highly differentiated TEMRA 
effector cells (Attig et al. 2009). Expression of several lymphocyte activation markers such as 
CD69 or HLA-DR on TILs has been confirmed and oligoclonal expansion of certain TCR-V 
regions indicates that a selection of potentially tumor specific T cells has taken place 
(Angevin et al. 1997). Furthermore, after isolation and ex vivo culture T cells are able to 
express cytokines and show normal cytotoxic activity. However if these TILs show 
functionality ex vivo then why are they not reactive within the tumor microenvironment? 
Indeed, freshly isolated uncultured TILs often show a reduced capacity of their cytotoxic 
function (Van den Hove, Van Gool et al. 1997) and also an impaired cytokine production or 
altered cytokine profile, demonstrating that some kind of immunosuppressive milieu must 
be present within the tumor microenvironment (Gouttefangeas et al. 2007). Defects in T-cell 
signalling and downregulation of the CD3 -chain, which is necessary for TCR signal 
transduction into the cell, can be frequently found in T cells isolated from RCC patients 
(Frey & Monu 2008). Several mechanisms responsible for this locoregional 
immunosuppression have been discovered within the last decades and only the most 
important findings will be described here. Some of these mechanisms, such as the activation 
of T regulatory cells (Tregs), have been intentionally developed by evolution to counteract 
deleterious long term activation of an immune response in order to avoid autoimmune 
diseases. Others, such as the generation of inhibitory signals have been developed or rather 
selected within the heterogeneity of tumor cells to escape an existing immune response and 
thereby provide a selection advantage. Among the latter are immunosuppressive cytokines  
IL-10 or TGF-, which are known to inhibit T-cell activation as well as proliferation and can 
also lead to downregulation of MHC class I molecules (Khong & Restifo 2002; Li et al. 2006). 
In renal cell carcinoma, proangiogenic vascular endothelial growth factor (VEGF), which 
acts also immunosuppressively by inhibiting DC maturation (Ohm & Carbone 2001) plays a 
major role because it is usually found highly overexpressed in clear cell RCCs (Rini 2005). 
Apart from the expression of immunosuppressive factors, tumor cells can also 
downregulate costimulatory molecules from their surface. Despite the fact that tumor cells 
are not professional APCs and therefore not supposed to prime T cells, the complete lack of 
costimulatory molecules such as CD80 (B7.1) or CD86 (B7.2) can lead to a decreased T-cell 
activation or even induction of T-cell anergy (Jung et al. 1999; Lang et al. 2000). In this 
context another B7 family member should be mentioned which, in contrast to the 
aforementioned, is often found highly upregulated in different types of cancer. B7-H1 
www.intechopen.com
 Immunotherapy of Renal Cell Carcinoma – From Antigen Identification to Patient Treatment 
 
199 
(PDL1) is usually expressed on macrophages and provides costimulatiory function for T 
cells. However, due to its high abundance on tumor cells it has a predominantly negative 
regulatory activity. After binding to its receptor PD1 on activated T cells B7-H1 can 
downmodulate T cell activation and even induce apoptosis (Dong et al. 2002). B7-H1, and 
more recently another associate of the B7 family with a similiar function, B7-H4, have been 
shown to be expressed in RCC patients and their expression correlated with adverse clinical 
prognosis (Thompson et al. 2005). 
In order to escape an already existing specific immune response, cancer cells can either 
escape by downregulating the antigen or even parts of the HLA presentation machinery. 
Indeed downregulation of HLA expression can be observed in several cancer types 
preferentially in late metastasized stages (Marincola et al. 2000; Campoli et al. 2002). 
Different mechanisms underlying this process of downregulation or even complete loss of 
HLA expression have been elucidated from several tumor cell lines and seem to affect 
nearly all parts of the antigen processing machinery (Seliger et al. 2002). To which extent 
HLA downregulation or loss plays a role in RCC is still controversial. Whereas some 
publications suggest that HLA downregulation is a frequent event (Romero et al. 2006) other 
more recent data could clearly show that HLA-expression is not diminished but rather 
upregulated in comparison to benign kidney tissue (Saenz-Lopez et al. 2010; Stickel et al. 
2011).   
Tumor cells can also indirectly inhibit an immune response by depriving proliferating 
immune cells of essential nutrients. Indoleamine-2,3-dioxygenase (IDO) is an enzyme that 
catalyzes the first and also rate-limiting step in the degradation of the essential amino acid 
tryptophane. IDO has been found to be nearly ubiquitously expressed in human tumors 
(Uyttenhove et al. 2003). By locally depleting tryptophane, IDO can inhibit the proliferation 
of TILs and also induce or recruit Tregs (Prendergast et al. 2009).  
CD4+ CD25high FoxP3+ regulatory T cells have become a major field of investigation in 
immunotherapy because of their potential to induce tolerance by suppressing (tumor) 
antigen specific priming of T cells and also T cell effector functions (Zou 2006). Tregs are 
known to accumulate within the microenvironment of different tumors (Woo et al. 2001) and 
higher levels of Tregs in the peripheral blood of cancer patients have been detected. In RCC 
patients a higher frequency of Tregs within the tumor and periphery have been described and 
correlate with an adverse clinical outcome (Liotta et al. 2011). A plethora of different 
mechanisms have been described on how Tregs exert their immunosuppressive functions that 
range from the expression of immunosuppressive cytokines (IL 10, TGF)(Taylor et al. 2006), 
induction of IDO and B7-H4 in APCs (Fallarino et al. 2003; Sica et al. 2003), and consumption 
of IL-2 (von Boehmer 2005) to direct cell mediated cytotoxicity (Grossman et al. 2004). 
Antigen specific Tregs have been described (Wang et al. 2004) but after activation, the 
suppressive activity of CD4+ Tregs seems to be antigen non-specific affecting T cells of 
varying specificity (Thornton & Shevach 2000). Another type of immunosuppresive cells are 
the myeloid derived suppressor cells (MDSCs) which have recently acquired increasing 
attention (Kusmartsev & Vieweg 2009). MDSCs are a heterogeneous population of 
progenitor cells of the myeloid lineage. Under healthy conditions these cells rapidly 
differentiate into mature granulocytes, macrophages and also dendritic cells. However, in 
patients suffering from different types of cancer that include RCC (Rodriguez et al. 2009), 
these immature cells have been shown to strongly accumulate in peripheral blood and also  
www.intechopen.com




Fig. 1. Immunosuppressive Mechanisms: (a) Overexpression of Indoleamin-2.3-
dioxyngenase (IDO) leads to reduced extracellular tryptophan levels thereby inhibiting T 
cell proliferation. (b) Defects in antigen presentation machinery or downregulation of MHC 
molecules prevent recognition by cytotoxic lymphocytes (CTLs). (c) Aberrant expression of 
PDL1 or upregulation of coinhibitory molecules B7-H4 decrease costimulation. (d) 
Downregulation of T-cell receptor (TCR) ζ-chain inhibits intracellular signalling. (e) 
Secretion of immunosuppressive cytokines by tumor cells or regulatory T cells (Tregs) 
inhibits activation of T cells (IL-10, TGF-β) and dendritic cells (VEGF). In addition induction 
of Tregs (f) from the CD4+ T helper cell (Th) population is inceased. (g) Infiltration of 
myeloid derived suppressor cells (MDSCs) from the blood lead to production of reactive 
oxygen species (ROS)) and enhanced arginine catabolism through arginase and iNOS 
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within the tumor microenvironment (Young et al. 1997; Nagaraj & Gabrilovich 2010) where 
they exert potent immunosuppressive effects. Myeloid suppressor cells seem to highly 
express two enzymes involved in the arginine metabolism: Arginase and inducible nitric 
oxid synthase (iNOS). These enzymes drive the enhanced catabolism of arginine which 
subsequently leads to an arginine depletion from the tumor microenvironment thereby 
strongly inhibiting T-cell proliferation (Ochoa et al. 2007; Gabrilovich & Nagaraj 2009). 
Higher arginase activity in PBMCs from RCC patients could indeed be demonstrated (Zea et 
al. 2005). Other mechanisms of MDSC mediated immunosuppression, such as the 
production of reactive oxygen species (ROS) e.g. peroxynitrite (Kusmartsev et al. 2004), the 
secretion of immunosuppressive cytokine TGF- (Filipazzi et al. 2007) and the induction of 
other immune suppressive cells such as Tregs (Serafini et al. 2008) could also be observed.  
Despite all these different immunosuppressive cells and the mechanisms discussed (see 
Figure 1), the infiltration of cancer tissue by leukocytes still remains a reliable marker for 
patient outcome and correlates positively with clinical prognosis in RCC patients (Pages et 
al. 2010). Galon et. al have shown that the presence and composition of the immunological 
infiltrate is highly predictive for clinical outcome in colon cancer patients and can even be 
superior to classical TNM staging (Galon et al. 2006).   
5. Counteracting immunosuppression 
In view of all these sophisticated immunosuppresive mechanisms there are doubts that we 
will ever be able to overcome immunosuppression and tumor escape. In order to generate a 
long lasting immune response which keeps the immune system up and running, tumor 
associated antigens ant T-cell epitopes represent only a part of the whole picture. Adjuvants 
are therefore urgently needed to specifically address this difficult task. Adjuvants 
or„Immunologist’s dirty little secrets“ as Janeway termed them (Janeway 1989) are an active 
component of most protective vaccines against infectious diseases particularly intended to 
enhance or modulate a specific immune response. Most of the adjuvants approved for 
human treatment (Alumn, MPL) were actually developed for passive vaccination of healthy 
patients against infectious diseases - a setting in which an enormously high safety profile of 
the adjuvant is clearly necessary. However, considering the highly immunosuppressive 
environment of late stage tumors in particular, the need for stronger immunostimulatory 
adjuvants has emerged even if  they reduce safety and bear the risk of provoking 
autoimmunity. In the majority of trials involving RCC patients (Table 1) cytokines such as 
GM-CSF, IL-2 or IFN have been used to ensure effective priming of T cells and enhance the 
immune response. Regardless of toxicity problems considering the systemic application of 
IL-2  and Interferon , new studies could show that IL-2 also leads to the induction and 
stimulation of regulatory T cells (Brandenburg et al. 2008). Similarly GM-CSF has been 
shown to stimulate the recruitment of myeloid derived suppressor cells (Serafini et al. 2004) 
and its beneficial effect in cancer vaccination has been challenged by two randomized 
vaccination trials in melanoma in which patients that additionally received GM-CSF had an 
inferior immunologic and patient outcome (Faries et al. 2009; Slingluff et al. 2009).  The use of 
incomplete Freund’s adjuvant and BCG as adjuvants in cancer immunotherapy appears 
rather outdated. Nevertheless, BCG is still approved for the treatment of superficial bladder 
cancer. Metabolizable squalene based emulsions (MF59, AF03) and saponins (Quil-A, 
ISCOM, QS-2) have replaced mineral oil based formulations like Freunds adjuvant. The use 
of live-attenuated bacteria like BCG has been discontinued in favor of molecularly defined 
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TLR agonists. The discovery that toll like receptors (TLRs) constitute part of the innate 
immune system and can act as pattern recognition receptors (PRRs) for different pathogen 
associated molecular patterns (PAMPs) has boosted the search for agonistic TLR ligands. 
Synthetic TLR ligands can, as their natural counterparts, bind to TLRs on different cell types 
and subsequently lead to the activation of the cell (e.g. maturation, release of 
proinflammatory cytokines, enhanced antigen presentation or effector function). In theory a 
combination of different TLR agonists can be used to tailor an immune response to fit 
individual needs (Adams 2009). For example, TLRs 3, 7/8 and 9 have been shown to lead to 
the preferential activation of a Th1 response which has been known for a long time to be a 
prognostic factor in cancer immunotherapy correlating with favourable outcome. Several of 
these synthetic TLR agonists such as PolyI:C (TLR3 agonist), Resimiquimod (TLR7/8 
agonist) and CpG (TLR9 agonist) are currently being evaluated  in clinical trials (Adams et 
al. 2008; Cheever 2008).  
Only very few studies in RCC patients have attempted to address the specific requirements 
needed to overcome immune escape. Some groups have used cyclophosphamide prior to or 
during vaccination because it is known that low doses of this chemotherapeutic drug lead to 
improved immune responses potentially by depleting Tregs. (Ghiringhelli et al. 2004; Lutsiak 
et al. 2005). Denileukin (Diftitox, Ontak), a recombinant fusion protein of IL-2 and diphtheria 
toxin has been also used successfully for the same purpose (Atchison et al. 2010). However 
some studies have described severe side effects in conjunction with Denileukin like vision 
loss and vascular leak syndrome (Park et al. 2007; Avarbock et al. 2008), treatment failure has 
also been reported (Welters et al. 2009). Recent studies are suggesting that pretreatment with 
less toxic Sunitinib might have a similar effect on regulatory T cells (Finke et al. 2008).  
The most promising agents that are currently being developed to overcome tumor induced 
immunosuppression are immune modulating antibodies that inhibit immune checkpoint 
controls (Fife & Bluestone 2008). The first antibody with this mode of action (Ipilimumab) 
has just recently been approved by regulatory authorities in the US and Europe as a 
monotherapy for the treatment of late stage melanoma. Ipilimumab is directed against 
cytotoxic T-lymphocyte antigen 4 (CTLA-4), a negative immunoregulatory receptor 
expressed by activated T cells, in particular Tregs. CTLA-4 binds to costimulatory molecules 
(e.g. CD80, CD86) on APCs or tumor cells and thereby directly competes with T cell 
coactivating molecule CD28. However whereas signalling through CD28 is leads to T cell 
activation CTLA-4 signalling is rather inhibitory and promotes T cell tolerization and 
anergy. Blocking of CTLA-4 by Ipilimumab consequently leads to an increase in T-cell 
activating signals resulting in a greatly sustained activation of an immune repsonse. 
Considering its unspecific mechanism of action it is not surprising that among the different 
side effects experienced after treatment with Ipilimumab, the induction of autoimmune 
phenomena was also quite frequent. Nevertheless, in most cases the treatment with 
corticosteroids was effective and did not interfere with clinical benefit.  
Based on this very recent breakthrough, several trials are currently evaluating combinations 
of Ipilimumab with targeted immunotherapeutic approaches in order to highlight the 
direction to activated T cells. Another immunomodulating antibody directed against PD1 
(MDX-1106) is currently being applied in late phase clinical trials. Interaction of PD1 with its 
ligand B7-H1, which is broadly overexpressed on tumor cells has already been discussed as 
an established tumor escape mechanism.  
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The advent of new immunotherapies has also clearly revealed another problem regarding 
the kinetics and study endpoints of clinical immunotherapeutic trials (Hoos et al. 2010). 
Evaluation of clinical benefit is usually based on world health organization (WHO) (World 
Health Organization. 1979) or response evaluation criteria in solid tumors (RECIST) 
(Therasse et al. 2000; Eisenhauer et al. 2009). These are criteria that were originally developed 
for treatment with cytotoxic agents. However, patterns of clinical response may greatly 
differ in immunotherapeutic trials. Compared to chemotherapeutics, the manifestation of 
clinical response is often delayed in immunotherapeutic trials and develops after an initial 
phase of stable disease or even tumor progression. This effect is frequently observed in 
immunotherapeutic trials and is expressed by a delayed separation of Kaplan-Meyer 
survival curves (Hoos et al. 2010). Furthermore, a well-known discrepancy of many 
immunotherapies that fail to achieve clinical benefit in progression-free survival but do 
show an objective effect on overall survival can be explained by this effect. In order to 
accommodate these observations, new immune related response criteria (irRC) have been 
proposed and are currently being tested for their significance and applicability in 
immunotherapeutical trials (Wolchok et al. 2009).  
Another question that remains in this context is the appropriate general setting of an 
immunotherapeutic approach. Nearly all trials mentioned in Table 1 focus on late stage 
patients with metastatic RCC that have often not responded to previous therapies and have 
acquired a resistance to cytokine treatment and targeted therapy. Some authors have 
suggested that this might be a rather unfavourable setting for testing the efficiency of an 
immunotherapeutic approach because the immune system has probably lost the battle 
against the cancer at a much earlier stge and immune suppressive mechanisms may have 
progressed to an irreversible state. The use of immunotherapies should therefore be tested 
preferentially in an adjuvant or minimal residual disease setting (Morse et al. 2005; Hoos et 
al. 2007).  
6. Tumor associated antigens: the good, the bad, and the ugly  
The lack of defined tumor specific antigens in RCC can already be deduced from the list of 
studies undertaken so far. Only few invoke defined antigens, most make use of autologous 
tumor tissue alone, in combination with adjuvant or after loading on dendritic cells. The use 
of non-defined antigens has several inherent problems however. First, the quality of the 
vaccine is critically dependent on the purity of the antigen and tissue material received from 
surgery is undoubtedly of varying quality. Furthermore, some studies have shown that only 
apoptotic and not necrotic cell vaccines can induce a regular immune response (Scheffer et 
al. 2003). Second, a mixture of different unknown antigens always has the potential of 
partially or preferentially inducing tolerogenic T cells or, even worse, inducing 
autoimmunity against self-antigens. Last but not least, immunomonitoring of patients, 
which has become a powerful tool in recent immunotherapeutic studies, can only be carried 
out accurately if the antigen is known in advance. Compared with full length proteins, 
antigenic peptides have the advantage of simple chemically defined production in GMP 
quality. This allows for the combination of different antigenic peptides to a multi-epitope 
vaccine. Thereby the individuality of a patient’s immune response is taken into account, 
indicating that not every patient will develop an equally strong immune response against 
one and the same antigen. The major disadvantage of defined T-cell epitopes is that they are 
usually restricted to for one HLA allotype requiring the patient to match to a certain HLA in 
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order to benefit from the treatment. This further underlines the need for the identification of 
additional tumor-associated antigen-derived peptides for less common HLA alleles (Klug et 
al. 2009). 
How can we now decide whether an identified antigen is also a good vaccination candidate 
and what are the hallmarks of these antigens? The most important but often carelessly 
neglected requirement of any good vaccination candidate is the presence of the antigen on  
the tumor cell. In terms of an immunotherapy this means that the antigen needs to be 
accessible in order to be recognized by immune cells, preferentially T cells. At first glance 
this sounds trivial but in fact most studies have made use of antigens that have actually 
never been found to be presented by MHC molecules and instead emanated from in vitro 
tested or in silico predicted T cell epitopes of previously known tumor associated antigens 
that were shown to be overexpressed within tumor tissue at the mRNA or protein level. In 
doing so basic principles of immunology are ignored since T cells are not given insight into 
tumor cells but have to rely on a showcase of peptide antigens presented by MHC 
molecules. Indeed it could be shown that the gene expression level of a certain protein and 
presentation of corresponding protein-derived peptides only reveal a very faint correlation 
(Weinzierl et al. 2007). 
The second most important requirement is the immunogenicity of the antigen. This is 
indeed a crucial point, since many of the tumor antigens are derived from self proteins and 
hence show only weak immunogenicity if at all because of central or peripheral T-cell 
tolerance. One great exception are unique antigens that arise from gene mutations or fusion 
proteins which accumulate during the course of tumor development. These neo-antigens are 
therefore not affected by tolerance mechanisms, either in the thymus during lymphocyte 
maturation by clonal deletion or in the periphery by anergy induction. Because of the large 
set of distinct mutations acquired within each tumor not only within different genes, but 
also at a multitude of locations within the gene, the application of mutated antigens in 
tumor vaccination will be restricted to a patient individualized approach.  
Other frequently examined antigens including cancer testis or differentiation antigens show 
a rather restricted expression pattern that can in some cases also be considered to be tumor 
specific. During the course of tumorigenesis cancer cells often acquire epigenetic alterations 
that lead to the expression of genes (MAGE, NY-ESO-1) which are usually only transcribed 
during embryonic development and hence remain silenced within adult tissue. Some of 
these cancer testis antigens (CTA) have, however, also been found to be expressed in thymic 
epithelium so that central tolerance by deletion of CTA-specific T cells cannot be excluded 
(Gotter et al. 2004). Differentiation antigens are commonly expressed in malignant and 
normal cells of the same lineage e.g. Melan-A, gp100 and TRP1 in melanoma tumor tissue 
and benign melanocytes. In cases in which the benign tissue expressing the differentiation 
antigen is dispensable as, for instance, in prostate cancer patients after prostatectomy, 
differentiation antigens like PSA become highly specific for the tumor. The great majority of 
potential vaccination antigens is, however, derived from tumor antigens that are rather 
ubquitously expressed but show a (high) overexpression on cancer tissue (CA9, Her2/neu, 
MUC1) (Kessler & Melief 2007). Differentiation and overexpressed antigens are usually 
subject to central and peripheral tolerance mechanisms. Self tolerance for many antigens, 
however is not always complete. The prior testing of T-cell immunogenicity for theses 
antigens is therefore absolutely essential.  
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Another aspect that should be considered before choosing a vaccination antigen is its impact 
on tumor oncogenicity. Preferentially, antigens should be targeted that are involved in the 
oncogenic process and hence indispensable for tumor growth and maintenance of the 
neoplastic state. 
Based on similar but not identical criteria, a ranking of potentially suitable tumor associated 
antigens for clinical use has been published in an initiative from the National Cancer 
Institute involving different working groups in the US (Cheever et al. 2009). They used an 
analytical hierachy process generated ranking which further included objective criteria like 
therapeutic functionality, the expression of the antigen within stem cells, number of patients 
expressing the antigen, the number of known antigen derived T-cell epitopes and also the 
cellular localisation of the antigen. 
7. Identification of new tumor associated antigens  
Having described the hallmarks of optimal tumor associated and specific antigens in the 
context of an anti-tumor vaccine we would now like to present state-of-the-art technology 
for the identification of respective antigens with a clear focus on tumor associated HLA 
ligands. There are several strategies which can be divided into two basic sets: Top-down 
approaches carried out - by directly analysing the tumor antigens present within or 
presented by tumor cells, and bottom-up. The latter represent a reverse approach usually 
starting from the gene level via the protein level and subsequently to the HLA ligand level.  
7.1 Bottom-up 
One of the first approaches developed for the large scale identification of tumor associated 
antigens is the serological identification of antigens by recombinant expression cloning 
SEREX (Sahin et al. 1995). The method is based on cDNA expression libraries created from 
tumor cell lines or tissues which are subsequently packaged into lambda-phage vectors that 
can be used to infect E. coli bacteria. During the lytic phase the production of recombinant 
proteins is induced and clones can be screened for the presence of tumor reactive antibodies 
using cancer patient sera. Selection, cloning and sequencing of antibody reacting clones 
allows for the straightforward molecular description of the antigen, as the recombinant 
proteins are located in the same E.coli clone plaque as the respective cDNA (Tureci et al. 
2005). The major advantage of cDNA expression libraries is that only genes that are actually 
expressed within the cell/tisue of origin are incorporated and that they can be generated 
from various sources that include patient derived autologous tumor tissue. SEREX is still a 
valued, commonly used tool for antigen identification (Wang et al. 2009; Kiyamova et al. 
2010). Several modifications have been incoporated to overcome restrictions for instance 
regarding the prokaryotic expression system, which does not allow for posttranslational 
modifications (Kim et al. 2007). With the advent of the „omics“ era a comparatively high 
throughput analysis of differences in the gene expression level could be done with relative 
ease. Now large databases summarizing these data are publicly available (Edgar et al. 2002). 
New approaches aim at gaining a deeper understanding of the tumor and its genetic basis 
by sequencing the complete tumor genome. The whole genome approach has profited from 
the rapid progress in next-generation sequencing techniques over the last few years which is 
fortunately accompanied by decreasing costs (Wong et al. 2011). The complete and 
differential sequencing of tumor tissue and corresponding normal tissue shows alterations 
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directly on genomic level that the tumor has acquired during its development (see Fig. 2 
blue section). The subset of potential tumor antigens can be assessed by the selection of non-
silent mutational events. Further reconciliation with databases of known sequence 
polymorphisms (dbSNP, (Smigielski et al. 2000)) or known mutations in cancer (COSMIC, 
(Bamford et al. 2004)) can help to distinguish tumor driver from passenger mutations.   
The bottom-up approach yields proteins without any post-translational modifications. A 
prerequisite for successful peptide vaccination therapy is the presentation on the tumor cell 
surface by MHC molecules. In silico digestion and HLA binding prediction (Feldhahn et al. 
2009) of the respective parts can shed light on which of these are putative tumor antigens 
suitable for further evaluation of immunogenicity in T-cell arrays. 
A major determinant for peptide:HLA binding is the steric configuration defined by the 
MHC molecule and the amino acid sequence of the peptide (Bjorkman et al. 1987). The HLA 
molecule forms a peptide binding groove with prominent binding pockets for individual 
amino acid side chains. The polymorphism of the HLA alleles results in different 
polypeptides and therefore different binding pocket properties. This yields characteristic 
peptide sequence motifs for ligands to bind the HLA molecule. The most conserved 
positions in these motifs form the anchor residues, whose side chains fit best in the binding 
pockets for strong interaction.  
With sufficient ligandome analysis that takes sequence statistics for the given peptide:HLA 
molecule pairs into consideration one can generate Position Specific Scoring Matrices 
(PSSMs). Each position holds higher scores for more frequently occurring amino acids. 
Summing up the scores for each position, these matrices can be used to estimate the binding 
capability with an HLA molecule for any given peptide sequence. The SYFPEITHI method 
uses PSSMs generated from naturally processed HLA ligands from the SYFPEITHI database 
(Rammensee et al. 1999) in an expert system fashion also accounting for given chemical 
conditions. The assumption of independent contribution of each amino acid to the overall 
binding affinity is one drawback of PSSM approaches. Non-linear fashion machine learning 
methods can create prediction models that address this issue with different techniques 
(support vector machine (SVM) based SVMHC (Dönnes & Kohlbacher 2006), artificial neural 
network (ANN) training method based NetMHC (Buus et al. 2003). Prediction quality for all 
approaches is heavily dependent on the sampling coverage for an an allele-specific HLA 
ligandome available (discussion of efficiency is out of scope). 
There also exist prediction methods for the steps preceding peptide presentation, the 
proteasomal cleavage of proteins (PAProC (Nussbaum et al. 2001), NetChop, (Kesmir et al. 
2002)) and the TAP transport (TAPPred, (Bhasin & Raghava 2004)). As these steps are very 
complex and depend on a huge variety of parameters, the results may not adequately reflect 
the naturally occurring process. The framework for T-cell epitope detection FRED provides 
easy accession to most prediction methods for MHC binding as well as creating a general 
infrastructure for the handling of antigen sequence data. It includes the possibility for 
integrated analysis of protein polymorphisms influences and simultaneous accession of 
different prediction methods. Analysis pipelines intended for high throughput capability 
profit immensely from such frameworks. They integrate different algorithms with differing 
input and output types and therefore provide a flexible means to implement of accelerating 
the analysis process. 
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7.2 Top-down  
Until now straightforward proteomics approaches have mainly focused on the identification of 
serum cancer biomarkers rather than target antigens for cancer therapy (Seliger et al. 2003). 
One exception is serological proteome analysis, SERPA, a modified SEREX approach 
translated to the protein level. In contrast to SEREX, screening with autologous patient sera is 
not carried out against cDNA expression libraries but against protein lysates separated by two 
dimensional polyacrylamide gel electrophoresis (2D-PAGE) or directly against protein arrays 
(Desmetz et al. 2009). The comparative full proteome analysis of tumor and benign tissue 
usually requires the pre-separation of proteins, for example by 2D-PAGE or multidimensional 
liquid chromatography, due to the overall complexity of the protein lysate. This approach has 
in the past suffered from low sensitivity and weak reproducibility (Baggerman et al. 2005). 
Identification of tumor associated target antigens has remained rare since standard proteomics 
approaches often fail to detect low abundant proteins (Joshi et al. 2011). Nevertheless 
proteomics is a rapidly developing field. Taking the steadily increasing mass spectrometric 
sensitivity (Yates et al. 2009), the use of in vitro (e.g. chemical modification) or in vivo (e.g. 
SILAC) differential labeling approaches for quantification (Schulze & Usadel 2010) and also 
MALDI imaging technology (Fournier et al. 2008) into account, proteomics will clearly 
contribute to a greater extent to TAA identification in the future.  
In contrast to standard proteomics, HLA ligandomics is a well established, straightforward 
approach and perfectly suited for the identification of tumor associated HLA ligands 
(Schirle et al. 2000). HLA molecules can be directly isolated from dissected tumors and 
autologous normal tissue. The method of choice is immunoaffinity chromatography using 
antibodies specific for different HLA molecules (see table 2) immobilised on a sepharose 
matrix. Application of a crude tissue lysate leads to the binding of respective HLA 
molecules which can be subsequently eluted by acid treatment. At the same time, pH shift 
also leads to the release of bound peptides from the HLA binding grooves. Due to the 
narrow mass range of these peptide ligands, they can be easily separated from higher 
molecular weight substances (>10 kDa) by ultra-filtration. Lyophilisation of the filtrate 
yields a mixture of different HLA derived peptides ready for concomitant separation and 
analysis using liquid-chromatography coupled mass spectrometry (LC-MS, see Fig. 2a). 
 
Clone ∝HLA Reference 
W6/32 A,B,C (Barnstable et al. 1978) 
B1.23.2 B,C (Rebai & Malissen 1983) 
BB7.2 A2 (Parham & Brodsky 1981) 
GAP-A3 A3 (Berger et al. 1982) 
Spv-L3 DQ (Spits et al. 1983) 
Tü-39 DR, DQ, DP (Maeda & Hirata 1984) 
L243 DR (Lampson & Levy 1980) 
IVD-12 DQ (Kolstad et al. 1987) 
Table 2. HLA directed antibodies 
The greates benefit is that the described procedure yields natural ligands, so that neither the 
proteasomal cleavage nor intracellular transport and loading onto HLA molecules has to be 
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determined for the respective peptide. The challenge is the molecular characterisation of the 
heterogenous mixture of isolated peptides. 
Peptide and protein sequencing can be accomplished via tandem mass spectrometry. This is 
an advanced technique of proteomics analysis and offers a versatile, high-throughput 
procedure for investigation of protein samples, including sequence identification. The 
measurement is conducted by recording the mass-to-charge ratio (m/z) of peptide ions with 
high sensitivity down to the sub-femtomole level. For better identification a second mass 
analyzer can be added in tandem, where molecules of selected masses are further 
fragmented (Roepstorff & Fohlman 1984; Johnson et al. 1987) and the resulting mass-to-
charge ratios measured (see Table 3). Fragmentation of peptides occurs most prominently at 
the backbone structure, i.e. the peptide bonds concatenating the amino acids. The result of a 
tandem mass spectrometric analysis is a spectrum of fragment m/z values. The fragments 
containing the N-terminus of the peptide are called „b-ions“ whereas those containing the 
C-terminus are called „y-ions“, each enumerated by the number of retained amino acids. Via 
the masses of the fragments the spectra can be annotated with the peptide’s sequence.  
 
b-ions Mass y-ions Mass 
1 (S) - YFPEITHI 1019.5197 8
2 SY 251.1026 FPEITHI 856.4563 7
3 SYF 398.1710 PEITHI 709.3879 6
4 SYFP 495.2238 EITHI 612.3352 5
5 SYFPE 624.2664 ITHI 483.2926 4
6 SYFPEI 737.3505 THI 370.2085 3
7 SYFPEIT 838.3981 HI 269.1608 2
8 SYFPEITH 975.4571 I 132.1019 1
 
Table 3. Theoretical fragmentation spectrum of SYFPEITHI peptide. 
Missing peaks make the spectrum annotation a complex problem. These are due to: 
technical detection thresholds, complex or incomplete fragmentation, contamination and 
measurement noise. This can be addressed by computational methods for mass 
spectrometry proteomics. Spectra can be identified by either algorithmic comparison to a 
database of known spectra (Eng et al. 1994), directly by de novo methods (Bertsch et al. 2009) 
that do not depend on databases or by comparison with a sequence database (Perkins et al. 
1999).  
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The latter and in most cases very robust method infers theoretical spectra from a set of 
compatible sequences and matches the experimentally determined masses with those 
calculated. The method is robust because it is possible to infer a statistical significance 
evaluation, i.e. a score, from the size of the database as well as the number and quality of 
matches. Another technique to introduce robustness to the results is the use of a false 
discovery cut off. The introduction of a decoy database (most commonly the inverse input 
database) allows for calculation of a false discovery rate, defined as the number of false 
discoveries (from the decoy) over the number of false and correct discoveries (from both 
databases) given a score. A false discovery rate of 5% discerns a score within one experiment 
which guarantees that scores equal or better will be false discoveries only by the chance of 
p=0.05 (i.e. 5%). 
Sophisticated methods for high throughput identification of natural HLA ligands are 
beginning to emerge. Established proteomics methods are specifically suited for this task. 
OpenMS (Sturm et al. 2008) is an open and flexible framework for proteomics data analysis. 
As explained, integrated analysis is a major advantage for high throughput oriented 
analysis. In the case of individualized cancer therapy, different disciplines with diverse 
methods come together which does not permit a comprehensive framework. One solution 
for maintaining high throughput capability is a tailored workflow development that 
integrates analysis tools of different trades. OpenMS/TOPP also comes with tools for 
workflow development (Kohlbacher et al. 2007) for virtually seamless integration of 
other computational aspects of immunology, such as the in silico prediction of HLA 
presented peptides or database connection and reconciliation containing very different 
types of data.  
7.3 Validation and selection of peptide candidates 
The final verification step of identified HLA ligands includes the chemical synthesis of 
peptides. The tandem mass spectrometric measurement of the synthesized peptide 
represents a crucial aspect of reliability. As fragmentation patterns define the sequence and 
are preserved throughout the measurements, the corresponding spectra as well as the 
retention time of the synthetic and identified peptide will be nearly identical. A putative T-
cell epitope needs to be further validated in T-cell priming experiments. For this reason a 
plethora of protocols has been established to prime naive T cells usually from healthy 
donors with either natural (e.g. dendritic cells) or artificial APCs presenting the synthetic 
peptide. Proliferation and priming efficiency can subsequently be assayed by a variety of 
functional tests, e.g. enzyme linked immunospot technique (ELISPOT), intracellular cytokine 
staining (ICS) or tetramer staining. 
In order to work reasonably well in a preferably diverse target group, the design of a 
vaccine also poses the challenge of combining several vaccination candidate peptides to a 
multi-epitope vaccine. Recently, Toussaint et al. (Toussaint & Kohlbacher 2009) proposed a 
mathematical framework for the selection of an optimal set of peptides for vaccination. 
Given a set of candidate epitopes, a target population, information on the respective T-cell 
reactivities to the peptides (or HLA binding affinities), along with other user-defined 
information to be incorporated in the selection process, the framework efficiently 
determines an optimal epitope set.  
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Fig. 2. The workflow for standard HLA ligandome analysis (red) and with mounted bottom-
up approach methods (blue) for patient individualisation. a) sample preparation, b) MS 
analysis, c) peptide identification, d) FDR filter, e) differential analys f) HLA ligand 
validation, g) vaccine design and application, h) genome sequencing, i) variation detection, 
j) peptide:HLA binding prediction, k) identification of peptides with sequence variation, l) 
targeted search. Chromosome figures are modified from a screenshot at 
http://genome.ucsc.edu (Kent et al. 2002).  
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The therapeutic situation in advanced stage renal cell carcinoma leaves much rome for 
improvement with frequent resistance development to TKIs and still no cure in sight. 
Despite the lack of convincing clinical succes, targeted immunotherapy remains a promising 
approach. We are only just beginning to understand the complex relationship between the 
tumor and the surrounding microenvironment. The sophisticated mechanisms of immune 
evasion that hamper an active immune response are still a major hindrance on the road to 
success. First steps to overcoming this are by specifically addressing immunosuppression 
presented through the advent of immune modulatory antibodies such as Ipilimumab. 
However improvement of targeted immunotherapy is also clearly dependent on the 
identification of new tumor associated and also specific antigens as well as HLA ligands 
(Stevanovic 2002). This stresses the need for concise epitope libraries comprising ligands 
from different tumor entities and benign tissue for various HLA alleles (Krüger et al. 2005). 
8.1 Targeting the individual patient 
The greatest leap forward in the struggle for a successful immunotherapy, at least from the 
authors’ point of view are expected from a patient individualised approach. Tremendous 
progress in DNA sequencing during the last few years has enabled us to look at the genetic 
basis of each individual cancer. Comparison of somatic mutations within different tumors 
has shown that distinct mutational patterns are not only present between different tumor 
types but also between tumors of the same entity clearly underlining the need for an 
individualized approach (Ocana & Pandiella 2010). 
Combination of whole genome sequencing with HLA ligandome analysis will in future lead 
to the identification of mutated tumor specific HLA ligands presented on tumor cells. The 
advanced utilisation of computer-aided high throughput methods enables fast and accurate 
identification of vaccine candidates. This demonstrates that individualised anti-tumor 
therapy is also feasible within a certain time frame (first vaccination estimated 5-7 weeks 
post surgery see Table 4). 
 
Step Approx. Duration Section in Figure 
2 
Genome sequencing > 2 Weeks Blue 
Ligandome analysis 1-2 weeks Red 
GMP grade peptide 
synthesis 
 
>2 Weeks Red 
 ∑ ~ 6 Weeks  
Table 4. Current time limitations until vaccine availability 
The use of mutated HLA ligands should also eliminate the need for time consuming in vitro 
T-cell immunogenicity testing since these antigens are tumor specific neoantigens and thus 
foreign to the immune system. Differences in the strength of an immune response towards a 
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certain mutated peptide antigen can, however, not be excluded. Nevertheless, the 
probability of response failure can be greatly reduced by a combination of several mutated 
peptides to a multi-epitope vaccine. 
Compared to other treatment strategies, immunotherapy aimed at mutated antigens does 
not necessarily need to target tumor driver mutations, which are usually key to oncogenic 
properties. Instead, any mutation specific for a certain tumor which is found to be expressed 
and presented by HLA molecules can be used. Thereby the amount of possible vaccination 
candidate peptides is greatly increased. The importance of this fact is obvious given that 
only 2-5 driver mutations among the 1000-10000 somatic mutations found can be 
unambiguously identified within each tumor (Stratton 2011). 
8.2 Targeting the tumor microenvironment 
Failure to eradicate cancer by targeting tumor cells exclusively has extended the focus in 
anticancer therapy during the last few years to include the tumor microenvironment (Kenny 
et al. 2007). Evidence is accumulating to confirm intense crosstalk between tumor cells and 
their surroundings. Tumor cells not just passively profit from nutritional factors but actively 
shape their own environment towards their specific needs in a process of coevolution 
(Polyak et al. 2009). Clear cell renal cell carcinoma are a prime example of this since they are 
usually hypervascularized. This is nearly always the result of a genetic defect in the hypoxia 
inducible factor 1 signalling cascade leading to secretion of large amounts of proangiogenic 
VEGF (Sufan et al. 2004). Other well established mechanisms of tumor-stroma interaction are 
the remodelling of the extracellular matrix by tumor-associated macrophages(Mantovani et 
al. 2006), the expression of stimulatory growth factors by tumor asociated fibroblasts 
(Bhowmick et al. 2004) and of course the attraction of immune suppressive cells (Baglole et 
al. 2006). The idea of targeting the cancer’s „safe haven“ might therefore not only deprive 
the tumor from its nutritional basis but hopefully also, at least in part reverse 
immunosuppression. Targeting the tumor stroma in RCC is already being done: tyrosine 
kinase inhibitors, which currently represent first line treatment for metastatic RCC, are 
thought to act primarily on endothelial cells, thereby inhibiting angiogenesis.  
Combination therapy of TKIs together with cytokine treatment (Miller & Larkin 2009) as 
well as TKIs with targeted immunotherapy (Rini et al. 2011) are already being tested in 
clinical trials. But what about targeting the stroma directly with a specific immunotherapy? 
Stroma cells within tumor cells seem to differ in various aspects from their normal 
counterparts. Endothelial cells within the tumor show a highly fenestrated chaotic 
organization and often lack supportive smooth muscle cells as well as a regular basement 
membrane (Aird 2009). Cancer associated fibroblasts have an activated phenotype with high 
proliferative capacity, less growth requirements and show a high capacity to recruit 
endothelial progenitor cells (Orimo & Weinberg 2006; Li et al. 2007). Differences between 
normal and tumor stroma can also be observed on the level of gene expression (Ma et al. 
2009) and are probably based on different epigenetic alterations (Hu et al. 2005). Some 
groups have reported that tumor associated stroma cells are also subject to clonally selected 
somatic mutations in tumor suppressor genes (TP53) (Kurose et al. 2002) and oncogenes 
(EGFR) (Weber et al. 2005) and further show a high degree of genomic instability (loss of 
chromosomal heterozygosity) (Moinfar et al. 2000). However these results are still 
controversial and might also be due to technical issues (Polyak, Haviv et al. 2009). 
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Nevertheless, considering the overall changes within tumor associated stroma might render 
these cells susceptible to an attack by different immune cells. In order to include the 
targeting of tumor stroma cells into an immunotherapeutic approach, immunological 
accessible antigens, especially HLA ligands which are exclusively expressed on tumor 
stroma need to be identified. 
8.3 Targeting cancer stem cells 
Another upcoming field in cancer therapy is based on the observation that tumor cells 
within some cancer types at least show a hierarchical organization which is closely 
resembling that of normal benign tissue. According to the cancer stem cell hypothesis only a 
rare population of tumor cells termed cancer stem cells (CSC) or tumor initiating cells (TIC) 
are ultimately responsible for initiating and driving tumor growth. CSCs share some 
characteristics with normal tissue stem cells including the potential of self renewal, 
indefinite division, slow replication rate, greatly increased DNA repair capacity and finally 
the ability to divide asymmetrically, thereby giving rise to new cancer stem cells and rapidly 
dividing more differentiated tumor cells that make up the bulk of the tumor (Wang & Dick 
2005). Evidence for the existence of a tumor initiating cell population was first provided in 
acute myeloid leukaemia by John Dick and colleagues in the mid 90s (Lapidot et al. 1994; 
Bonnet & Dick 1997). They demonstrated that tumorigenicity of leukaemia cells was much 
higher in a subpopulation of CD34+CD38- tumor cells. Less than 500 cells exhibiting this 
particular phenotype were sufficient to engraft immunodeficient mice, whereas even a 100-
fold higher number of CD34+CD38+ tumor cells, which constitute the gross of leukaemic 
cells, could not initiate engraftment. Even more important engraftment of isolated 
CD34+CD38- cells repeated the composition of the original tumor in that CD34+CD38- cells 
also gave rise to the major leukaemic cell population of CD34+CD38+ cells. 
Several years later, the presence of a cancer stem cell population in solid tumors was shown 
for breast cancer (Al-Hajj et al. 2003). Since then, the existence of a CSC-population has been 
shown for many different types of cancer including brain, prostate, liver, colon and lung (for 
a review see (Visvader & Lindeman 2008)). In renal cell carcinoma, the existence of a CD105+ 
cancer stem cell population has also been postulated but final proof regarding its existence 
is still missing (Bussolati et al. 2008). The attraction of the cancer stem cell model is in part 
based on its ability to explain  long known but still poorly understood clinical phenomena, 
the relapse of cancer patients after a period of tumor regression and even absence of 
detectable lesions. CSC are known to be highly resistant to chemo- and radiotherapy. They 
can remain quiescent for a prolonged period of time and then restart tumor growth at a 
distant site leading to metastasis. This bears a fundamental clinical impact for the treatment 
of cancer patients. As long as CSCs are not effectively killed by a treatment we won’t be able 
to completely eradicate a certain tumor (Clevers 2011). Considering the resistance 
mechanisms to standard therapeutic approaches, immunotherapy may indeed be the only 
therapeutic option to directly target these cells. Therefore  cancer stem cell specific antigens 
urgently need to be discovered and their potential for a targeted immunotherapy evaluated.  
There is ample evidence that specific immunotherapy will play a very important role in the 
future not only in RCC but rather for the treatment of different cancer types. The first 
targeted immunotherapy Provenge (Sipuleucel-T) manufactured by Dendreon has just 
recently been approved by the FDA for the treatment of advanced prostate cancer. Provenge 
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consists of an autologous dendritic cell vaccine loaded with a fusion protein of GM-CSF 
with the prostate specific antigen prostatic acid phosphatase (PAP). Although it is far too 
early to speak of a triumphal course of this new category of cancer treatment at least a start 
has been made. 
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